Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

In a major scientific breakthrough, researchers at Stanford University have used artificial intelligence (AI) to design entirely new viruses that do not exist in nature.

The AI-generated viruses successfully killed Escherichia coli (E. coli) bacteria that had become resistant to naturally occurring bacteriophages (phages)—viruses that infect and destroy bacteria—offering new hope for tackling antibiotic-resistant infections.

The study, published in the journal Science, also raises important biosafety concerns, as the same technology could potentially be misused to design harmful pathogens.

How AI Created the Viruses?

Chemical engineer Brian Hie and bioengineering graduate student Samuel King developed Evo 2, a generative AI model capable of writing complete DNA sequences and designing entirely new genomes.

The researchers focused on bacteriophages, viruses that infect bacteria and are already being explored as alternatives to antibiotics for treating difficult bacterial infections.

Using genomes designed by Evo 2, the team synthesized nearly 300 novel phages and tested them against E. coli. From these, they identified 16 highly effective phages that successfully killed bacteria resistant to naturally occurring phages.

The researchers believe the ability to rapidly design customized phages could transform phage therapy and expand the arsenal against antibiotic-resistant bacteria.

The team redesigned bacteriophage ΦX174, one of the simplest known viruses. Despite its small size, ΦX174 efficiently infects and kills bacteria, making it a valuable model for developing new phage therapies.

A New Weapon Against Antibiotic Resistance

One of the biggest challenges in infectious disease treatment is that bacteria eventually develop resistance to antibiotics—and even to individual phages. To overcome this, the researchers designed a genetically diverse cocktail of 16 AI-created phages.

"If the bacteria gain resistance to a single phage, it's game over for the medication," Hie said. "But if you have multiple genetically distinct phages in a mixture, it would be harder for the bacteria to develop resistance to the entire cocktail."

The team showed that the phage cocktail successfully eliminated E. coli strains that had become resistant to the natural ΦX174 virus.

"We have a proof of concept in the paper, where we show that this cocktail of 16 phages rapidly overcomes resistance in E. coli that is immune to native ΦX174," Hie said.

Potential Beyond E. coli

Researchers believe the same AI-driven approach could eventually be used to develop phages against other drug-resistant bacteria, including:

• Mycobacterium tuberculosis (tuberculosis)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Pseudomonas aeruginosa, a leading cause of antibiotic-resistant hospital-acquired infections

If successful, AI-designed phage cocktails could provide a powerful alternative to conventional antibiotics, whose effectiveness continues to decline because of antimicrobial resistance.

Biosafety Concerns Grow

The researchers have made Evo 2 freely available as open-source software, allowing scientists around the world to design and study new genomes.

While this could accelerate advances in medicine and biotechnology, experts say it also highlights the urgent need for stronger oversight.

"The ability to compose viral genomes using generative AI now exists; the governance to safely steer it does not," wrote Prof. Tom Inglesby and Dr. Moritz Hanke of the Center for Health Security at Johns Hopkins University in an accompanying Science commentary.

Tom Ellis, Professor of Synthetic Genome Engineering at Imperial College London, described the research as impressive but cautioned that AI could theoretically be used to design harmful viruses if trained on the genetic code of dangerous pathogens, The Guardian reported.

However, he said safeguards—such as restricting access to sensitive genetic data and screening synthetic genomes before they are manufactured—could help reduce those risks.

The Donald Trump administration is reportedly considering an executive order focused on the US childhood vaccination schedule and autism research, despite decades of scientific evidence showing no link between vaccines and autism.

According to a Washington Post report citing official sources, the proposed order would examine the childhood immunization schedule and autism research. However, its scope and timing have not been finalized and could still change.

The move comes even as some of Trump's political advisers have reportedly warned that elevating the issue could hurt Republican candidates ahead of the November midterm elections.

White House Pushes Greater Scrutiny of Vaccines

According to The Wall Street Journal, Trump wants "alleviating autism" to become part of his presidential legacy and has privately expressed frustration that US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has not gone far enough in reducing the recommended childhood vaccination schedule. The report also said Trump believes that reducing the number of recommended childhood vaccines could lower autism rates.

In recent months, Trump has urged senior administration officials, including Kennedy Jr., to increase scrutiny of childhood vaccines.

Last year, Kennedy had cancelled roughly $500 million in mRNA vaccine research grants and replaced every member of a federal immunization advisory panel. However, he has been relatively quiet on vaccine policy this year after White House aides reportedly advised that vaccine skepticism was unpopular with many voters.

Scientists Reject Vaccine-Autism Link

Medical experts continue to emphasize that extensive research has found no evidence that vaccines cause autism.

"Donald Trump has been anti-vaccine at least since 2015," Dr. Paul Offit, Director of the Vaccine Education Center and an infectious disease specialist at Children's Hospital of Philadelphia, was quoted as saying by CNN.

During the 2015 Republican primary debate, Trump claimed autism had gotten "totally out of control" and suggested vaccines should be administered in "smaller doses over a longer period of time."

Trump Repeats Claims on Childhood Vaccines

Trump has repeatedly suggested there may be a connection between vaccines and autism, despite overwhelming scientific evidence disproving the claim. He has also argued that the US childhood vaccination schedule should be reduced, raising concerns among public health experts.

"I believe in vaccines, but I don't believe that, you know, you have to have a mandate for all of them," Trump said in a May interview with journalist Sharyl Attkisson. "I really feel that vaccines, if they were given in smaller quantities—they want to cut some out, and that's good, too. I agree with that."

Scientific Consensus Remains Unchanged

Multiple large-scale studies conducted over the past two decades have consistently found no causal link between childhood vaccines—including the MMR vaccine—and autism spectrum disorder.

Major health organizations, including the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC), continue to recommend routine childhood immunization as one of the safest and most effective ways to prevent infectious diseases.

Alex Hughes, the son of former Wales and Manchester United footballer Mark Hughes, has died at the age of 38 from Sudden Arrhythmic Death Syndrome (SADS), also known as Sudden Adult Death Syndrome.

Alex Hughes, who served as Grimsby Town's Head of Player Recruitment, was found collapsed on the bedroom floor of his Cheshire home by his two sons at around 7 a.m. on June 19, an inquest at Cheshire Coroner's Court heard.

According to the hearing, Alex's eldest son immediately began CPR before paramedics arrived. Despite prolonged resuscitation efforts, emergency responders were unable to revive him.

Area Coroner Victoria Davies concluded that Hughes died from Sudden Arrhythmic Death Syndrome (SADS), a condition in which a fatal heart rhythm abnormality causes sudden cardiac arrest even though the heart appears structurally normal during a post-mortem examination.

Following his death, Mark Hughes and his wife, Jill, said they were "totally heartbroken by the sudden and unexpected loss of our beloved son."

What Is Sudden Arrhythmic Death Syndrome (SADS)?

SADS refers to a sudden, unexpected death caused by an abnormal heart rhythm in people whose hearts appear structurally normal after death. The condition is most commonly linked to inherited disorders that affect the heart's electrical system, triggering life-threatening irregular heart rhythms (arrhythmias) that can lead to sudden cardiac arrest.

According to the British Heart Foundation, around 500 people die from SADS each year in the UK, with young adults—particularly men—being most commonly affected.

What Causes SADS?

Most cases of SADS are caused by inherited genetic conditions that interfere with the heart's electrical signals. Because these disorders often cause few or no symptoms, many people remain unaware they have them until a cardiac arrest occurs.

Early diagnosis through cardiac evaluation and family screening can help identify those at risk and prevent sudden deaths.

Inherited Conditions Linked to SADS

Several inherited heart rhythm disorders are associated with SADS, including:

• Brugada syndrome: Causes dangerous abnormal rhythms in the heart's lower chambers (ventricles).
• Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT): Triggers dangerously fast heart rhythms during exercise or emotional stress.
• Long QT syndrome (LQTS): Delays the heart's electrical recovery between beats, increasing the risk of life-threatening arrhythmias.
• Short QT syndrome (SQTS): Causes the heart to recharge too quickly, raising the risk of atrial fibrillation and ventricular arrhythmias.
• Timothy syndrome: A rare form of Long QT syndrome associated with severe heart rhythm abnormalities.
• Wolff-Parkinson-White (WPW) syndrome: An extra electrical pathway in the heart causes episodes of rapid heartbeat.

Symptoms That May Signal SADS

Many people with inherited heart rhythm disorders experience no warning signs. However, symptoms that warrant medical evaluation include:

• Fainting or seizures, particularly during exercise, excitement or emotional stress.
• Chest pain during physical activity.
• Shortness of breath while exercising.
• Episodes of rapid or irregular heartbeat (palpitations).
• A family history of unexplained sudden cardiac death.